Antagonistic and agonistic effects of quinazoline tyrosine kinase inhibitors on mutant EGF receptor function

International Journal of Cancer

Volumn 101, Issue 2, 2002, Pages 111-117

  Montgomery, R Bruce ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Division of Oncology   (United States)

Author keywords

Dimerization; EGFR; Mutant; Quinazoline; Tyrosine kinase; Tyrphostin

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; AGAR; DIMER; EPIDERMAL GROWTH FACTOR RECEPTOR; MATRIGEL; MITOGEN ACTIVATED PROTEIN KINASE; MUTANT PROTEIN; PHOSPHOTYROSINE; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; TYRPHOSTIN; TYRPHOSTIN AG 1517; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; AUTOPHOSPHORYLATION; CELL LINE; CELL TRANSFORMATION; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIMERIZATION; DRUG ACTIVITY; DRUG EFFECT; ENZYME ACTIVITY; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

3T3 CELLS; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CELL DIVISION; CELL LINE; CELL SIZE; CELL TRANSFORMATION, NEOPLASTIC; DIMERIZATION; GRB2 ADAPTOR PROTEIN; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; MUTATION; NEOPLASM INVASIVENESS; PHOSPHORYLATION; PROTEINS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TYRPHOSTINS;

EID: 0037056218     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10560     Document Type: Article

References (36)

1. Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification
2. Transformational and altered signal transduction by a naturally occurring mutant EGF receptor
3. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity
4. Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway
5. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors
6. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases
7. Growth factors and cancer
8. The antiproliferative effects of tyrosine kinase inhibitors tyrphostins on a human squamous cell carcinoma in vitro and in nude mice
9. 4,5-Dianilinophthalimide: A protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity
10. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase
11. Tyrosine kinase inhibition: An approach to drug development
12. Selective inhibition of the epidermal growth factor and HER2/neu receptors by tyrphostins
13. Differential modulation of mitogen-activated protein (MAP) kinase/extracellular signal-related kinase kinase and MAP kinase activities by a mutant epidermal growth factor receptor
14. Epidermal growth factor receptor stimulation of diacylglycerol kinase
15. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor
16. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis
17. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling
18. Activation of the Ras/mitogen-activated protein kinase pathway by kinase-defective epidermal growth factor receptors results in cell survival but not proliferation
19. An incomplete program of cellular tyrosine phosphorylations induced by kinase-defective epidermal growth factor receptors
20. A kinase-negative epidermal growth factor receptor that retains the capacity to stimulate DNA synthesis
21. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma
22. Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site
23. Use of a reconstituted basement membrane to study the invasiveness of tumor cells
24. Protein binding modulates inhibition of the epidermal growth factor receptor kinase and DNA synthesis by tyrphostins
25. The MAPK signaling cascade
26. Sos1 rapidly associates with Grb2 and is hypo-phosphorylated when complexed with the EGF receptor after EGF stimulation
27. EGF-induced SOS phosphorylation in PC12 cells involves P90 RSK-2
28. Insulin receptor-mediated dissociation of Grb2 from Sos involves phosphorylation of Sos by kinase(s) other than extracellular signal-regulated kinase
29. Suppression of invasion and MMP-9 expression in NIH 3T3 and v-H-Ras 3T3 fibroblasts by lovastatin through inhibition of ras isoprenylation
30. α6β4 and α6β1 integrins associate with ErbB-2 in human carcinoma cell lines
31. BE-23372M, a novel and specific inhibitor for epidermal growth factor receptor kinase
32. Receptor blockade with monoclonal anti-bodies as anti-cancer therapy
33. A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors
34. Tyrphostins IV - Highly potent inhibitors of EGF receptor kinase. Structure-activity relationship study of 4-anilidoquinazolines
35. Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors
36. Switching signals on or off by receptor dimerization